(Total Views: 815)
Posted On: 08/05/2020 7:40:34 AM
Post# of 154009
Quote:
One would assume/hope that if the DSMB sees great stat sig in one of the secondary endpoints at n=195, that they would recommend a similar change.
DSMB won't be handling the interim analysis at 195 patients that will be Amarex's job. Then it's up to Cytodyn to submit to the FDA if results support doing so.
(2)
(0)
